Clinical Research
Along with normal clinical service, wide range of clinical trials also provided in our center
We are actively recruiting patient to participate in the following clinical trials
Please send referral letter to medicaloncology@hku.hk if interested
Recruiting clinical Trials
Breast Cancer
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
CLEE011O12001 (ADJUVANT WIDER)
A phase IIIb study to characterize the effectiveness and safety of Adjuvant ribociclib in wide patient populations with HR+ HER2- early breast cancer
Ribociclib + AI
OBI-822-011
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer
OBI-822, OBI-821
VS
Placebo
CO44657 (PionERA)
A Phase III, randomized, open-label study evaluating efficacy and safety of giredestrant compared with fulvestrant,bboth combined with a cdk4/6 inhibitor, in patients with estrogen receptor-positive, her2-negative advanced breast cancer with resistance to prior adjuvant endocrine therapy
Giredestrant + CDK4/6
VS
Fulvestrant + CDK4/6
GS-US-592-6173 (Ascent -04)
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
Sacituzumab Govitecan-hziy (SG) + Pembrolizumab
VS
Pembrolizumab + Treatment of Physician's Choice (TPC)
OP-1250-301
(Opera-01)
A phase 3 randomized, open-label study of OP-1250 monotherapy vs standard of care for the treatment of ER+, HER2- advanced or metastatic breast cancer following endocrine and CDK4/6 inhibitor therapy (OPERA-01)
OP-1250
VS
Treatment of Physician's Choice (TPC)